


**Amendments to the Claims:**

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (currently amended) A compound of the following Formula I:



I

wherein:

R<sub>1</sub> has the formula alkylene-L-R<sub>1-1</sub>, alkenylene-L-R<sub>1-1</sub>, or alkynylene-L-R<sub>1-1</sub>, wherein:

the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more -O- groups;

L is a bond or a functional linking group selected from the group consisting of -NH-S(O)<sub>2</sub>-, -NH-C(O)-, -NH-C(S)-, -NH-S(O)<sub>2</sub>-NR<sub>3</sub>-, -NH-C(O)-NR<sub>3</sub>-, -NH-C(S)-NR<sub>3</sub>-, -NH-C(O)-O-, -O-, -S-, and -S(O)<sub>2</sub>-; and

R<sub>1-1</sub> is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

R'' is selected from the group consisting of:

hydrogen;  
alkyl;  
alkenyl;  
aryl;  
heteroaryl;  
heterocyclyl;  
alkylene-Y-alkyl;  
alkylene-Y-alkenyl;  
alkylene-Y-aryl; and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;  
 halogen;  
 $-N(R_4)_2$ ;  
 $-C(O)-C_{1-10}alkyl$ ;  
 $-C(O)-O-C_{1-10}alkyl$ ;  
 $-N_3$ ;  
 aryl;  
 heteroaryl;  
 heterocyclyl;  
 $-C(O)-aryl$ ; and  
 $-C(O)-heteroaryl$ ;

wherein aryl is phenyl, naphthyl, biphenyl, fluorenyl or indenyl; heteroaryl is furyl, thienyl, pyridyl, quinoliny, isoquinoliny, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxaliny, benzothiazolyl, naphthyridiny, isoxazolyl, isothiazolyl, puriny, quinazoliny, pyraziny, or 1-oxidopyridyl; and heterocyclyl is the fully saturated or partially unsaturated derivative of any one of the above heteroaryl groups, pyrrolidiny, tetrahydrofuranyl, morpholiny, thiomorpholiny, piperidiny, piperaziny, thiazolidiny, imidazolidiny, isothiazolidiny, tetrahydropyranyl, quinuclidiny, or homopiperidiny;

wherein: Y is  $-O-$  or  $-S(O)_{0-2}-$ ; and each  $R_4$  is independently selected from the group consisting of hydrogen,  $C_{1-10}alkyl$ , and  $C_{2-10}alkenyl$ ;

$R_A$  and  $R_B$  are each independently selected from the group consisting of:

\_\_\_\_\_ hydrogen;  
 \_\_\_\_\_ halogen;  
 \_\_\_\_\_ alkyl;  
 \_\_\_\_\_ alkenyl;  
 \_\_\_\_\_ alkoxy;

alkylthio, and

~~N(R<sub>3</sub>)<sub>2</sub>;~~

~~or when taken together, R<sub>A</sub> and R<sub>B</sub> to form a fused benzenearyl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups;~~

~~or when taken together, R<sub>A</sub> and R<sub>B</sub> form a fused 5- to 7-membered saturated ring; optionally not containing ~~a~~one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;~~

each R is independently selected from the group consisting of

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,

alkoxy,

alkylthio, and

-N(R<sub>3</sub>)<sub>2</sub>; and

each R<sub>3</sub> is independently selected from the group consisting of hydrogen and alkyl;

with the proviso that when L is -NH-S(O)<sub>2</sub>- and R<sub>A</sub> and R<sub>B</sub> join to form an unsubstituted benzene ring, R<sub>1-1</sub> is a linear or branched aliphatic group having greater than 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds; ~~and with the further proviso that when L is -NH-C(O)- and R<sub>A</sub> and R<sub>B</sub> join to form an unsubstituted pyridine ring, R<sub>1-1</sub> is a linear or branched aliphatic group having greater than 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;~~  
or a pharmaceutically acceptable salt thereof.

2-6 (canceled)

7. (previously presented) The compound or salt of claim 1 wherein R<sub>A</sub> and R<sub>B</sub> form a fused benzene ring which is unsubstituted.

8-10 (canceled)

11. (previously presented) The compound or salt of claim 1 wherein L is a bond or a functional linking group selected from the group consisting of -NH-C(O)-, -NH-S(O)<sub>2</sub>-, and -NH-C(O)-N(R<sub>3</sub>)-.

12. (canceled)

13. (previously presented) The compound or salt of claim 1 wherein R<sub>1-1</sub> is a linear or branched aliphatic group having 12-20 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds.

14. (original) The compound or salt of claim 13 wherein R<sub>1-1</sub> is a straight chain C<sub>12</sub>-C<sub>20</sub>alkyl.

15-16 (canceled)

17. (previously presented) The compound or salt of claim 1 wherein R<sub>1</sub> has the formula C<sub>1-5</sub>alkylene-L-R<sub>1-1</sub> and the C<sub>1-5</sub>alkylene is optionally interrupted with one -O- group.

18. (previously presented) The compound or salt of claim 1 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, alkyl, and alkylene-O-alkyl.

19 (canceled)

20. (currently amended) A compound of the following Formula III:



III

wherein:

$R_1$  has the formula alkylene-L- $R_{1-1}$ , alkenylene-L- $R_{1-1}$ , or alkynylene-L- $R_{1-1}$ , wherein:

the alkylene, alkenylene, and alkynylene groups are optionally interrupted with one or more -O- groups;

L is a bond or a functional linking group selected from the group consisting of -NH-S(O)<sub>2</sub>-, -NH-C(O)-, -NH-C(S)-, -NH-S(O)<sub>2</sub>-NR<sub>3</sub>-, -NH-C(O)-NR<sub>3</sub>-, -NH-C(S)-NR<sub>3</sub>-, -NH-C(O)-O-, -O-, -S-, and -S(O)<sub>2</sub>-; and

$R_{1-1}$  is a linear or branched aliphatic group having at least 11 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;

R is selected from the group consisting of

halogen,  
hydroxy,  
alkyl,  
alkenyl,  
haloalkyl,  
alkoxy,  
alkylthio, and  
-N(R<sub>3</sub>)<sub>2</sub>;

n is 0 to 4;

$R_2$  is selected from the group consisting of:

hydrogen;  
alkyl;  
alkenyl;  
aryl;

heteroaryl;  
heterocyclyl;  
alkylene-Y-alkyl;  
alkylene-Y-alkenyl;  
alkylene-Y-aryl; and  
alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;  
halogen;  
-N(R<sub>4</sub>)<sub>2</sub>;  
-C(O)-C<sub>1-10</sub>alkyl;  
-C(O)-O-C<sub>1-10</sub>alkyl;  
-N<sub>3</sub>;  
aryl;  
heteroaryl;  
heterocyclyl;  
-C(O)-aryl; and  
-C(O)-heteroaryl;

wherein aryl is phenyl, naphthyl, biphenyl, fluorenyl or indenyl; heteroaryl is furyl, thienyl, pyridyl, quinoliny, isoquinoliny, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxaliny, benzothiazolyl, naphthyridiny, isoxazolyl, isothiazolyl, puriny, quinazoliny, pyraziny, or 1-oxidopyridyl; and heterocyclyl is the fully saturated or partially unsaturated derivative any one of the above heteroaryl groups, pyrrolidiny, tetrahydrofuranyl, morpholiny, thiomorpholiny, piperidiny, piperaziny, thiazolidiny, imidazolidiny, isothiazolidiny, tetrahydropyranyl, quinuclidiny, or homopiperidiny;

Y is -O- or -S(O)<sub>0-2</sub>;

each R<sub>4</sub> is independently selected from the group consisting of hydrogen, C<sub>1-10</sub>alkyl, and C<sub>2-10</sub>alkenyl; and

$R_3$  is selected from the group consisting of hydrogen and alkyl;  
with the proviso that when L is  $-NH-S(O_2)-$ , and n is 0,  $R_{1-1}$  is a linear or branched aliphatic group having at least 16 carbon atoms, optionally including one or more unsaturated carbon-carbon bonds;  
or a pharmaceutically acceptable salt thereof.

21. (original) The compound or salt of claim 20 wherein n is 0.

22-23 (canceled)

24. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

25. (withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

26-27 (canceled)

28. (withdrawn) A method of vaccinating an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal as a vaccine adjuvant.

29. (withdrawn) A method of vaccinating an animal comprising administering an effective amount of *N*-(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)hexadecanamide to the animal as a vaccine adjuvant.

30-32 (canceled)

33. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 20 in combination with a pharmaceutically acceptable carrier.
34. (withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 20 to the animal.
35. (withdrawn) A method of vaccinating an animal comprising administering an effective amount of a compound or salt of claim 20 to the animal as a vaccine adjuvant.